arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Armata Pharmaceuticals, Inc.

ARMP
$3.62 ▼ -0.60 (-14.22%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
55 Visible periods
21 Metrics
Peer-ranked Benchmarks
Price Chart
78
Health
Good
Bullish
auto_awesome

Analytical Summary

Armata Pharmaceuticals, Inc. shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $133.0M
Dividend Yield
Revenue Growth
Op. Margin
ROIC 3.5%
FCF / Share $-0.24
Trailing P/E 1.8x
Price / Book
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

55-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$74.14M
↑ +164.3%
FCF / Share Free cash flow per share
$-0.24
↓ -47.7%
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Returns
99
Cash Quality
28

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 14 years · 55 quarters